Israel Writing Playbook to Become Cannabis Gateway to Europe
November 21st, 2019
App, Exclusive, News, Top Story
With unprecedented expertise in cannabis research and perfect weather conditions for cultivation, it only makes sense that Israeli lawmakers took a global leadership position in January 2019 by green-lighting the export of medical cannabis to countries where it is allowed. Then it just became a matter of establishing the framework to become one of only a small handful of countries to allow for cannabis exports. In doing so, Israel is opening a large market for itself and capitalizing on technology that it has developed over decades, rather than letting it go to other countries.
The Ministry of Health is not sitting on its hands with implementing change. Late last week in a statement to the High Court of Cannabis, the health regulator said it will be releasing its guidelines on exports any day now. Of particular interest, the statement read (translated), “For the Ministry of Health, any business that meets the standard for local production and marketing – can market its products abroad.”
That is music to the ears of Isracann Biosciences (CSE: IPOT) (OTC: ISCNF), the first North American-listed pure-play cannabis firm based in the heart of Israel’s agricultural sector. Isracann is fully-funded for a 230,000 square-foot facility with an annual capacity of 23,500 kilograms of dried cannabis that will feed demand in its underserved domestic market as well as the burgeoning European markets. Owing to the climate and existing infrastructure, Isracann estimates it will be able to produce high-end cannabis at just $0.40 per gram, a cost point that will facilitate high margins compared to others in the industry.
Click Here To Receive Isracann’s Investor Presentation
Ministry of Health Demanding Production
The Ministry of Health is looking to keep an orderly market between the roughly 20 public cannabis companies and dozens of private outfits. To the point, the regulator expects the owners of the licenses to produce, warning that dealers must fulfill the terms of their license to move products through the supply chain at the appropriate price and quantity or “the Ministry of Health will use all the tools at his disposal, including the revocation of the license.
While the decision by the Israeli government to support exports was made in January, just how the market will look has been a little murky. The Ministry of Health moving forward is a big step towards meeting the goal of export framework being in place early in 2020.
The MOH is also looking to silence a growing choir of voices alleging that cannabis reform has hamstrung domestic supply and caused a spike in prices, ultimately limiting access to cannabis medication that 46,000+ Israeli patients are accustomed to.
Given that the patient population in Israel is forecast to rise to 90,000 by 2020, there is some sense of urgency to institute change and bolster the smaller domestic supply chain while the much larger export market emerges, which falls right into the business plans of Isracann and its agreements within Israel for medicinal marijuana cultivation.
Of course, exports are a two-way street and regulations must also be established in the importing countries that align with Israel’s export laws. Isracann is looking to multiple opportunities in Europe, with Germany, the E.U.’s biggest economy, the top priority. The E.U. medical marijuana market is forecast to reach $64 billion by 2028.
Recently, Isracann added to its coffers with a successful funding round raising a net of C$10.1 million, a cash hoard that is allowing management to accelerate development of phase 1 of its new cultivation campus. Isracann isn’t going it alone, it has support from its regional partners holding preliminary breeding and cultivation licenses from the Ministry of Health.
Click Here To Receive Isracann’s Investor Presentation
These stakeholders are responsible to license upkeep, as well as the cost of electricity, property and related land taxes, in addition to participating in the construction of the greenhouse facilities.
This month, Isracann engaged AgroPlan Ltd. and A.R. Factor Group, two esteemed Israel-based companies specializing in construction of agricultural and cannabis facilities. AgroPlan is preparing the architectural design and engineering drawings for the cultivation and harvest facilities. A.R. Factor is handling the security design, while the two work together on the critical input to ensure the facility will be compliant with Israeli Medical Cannabis – Good Security Practices code.
“Engaging leading consultants to assist and guide us through the process helps ensure we meet our aggressive timelines and goals,” commented Isracann CEO Darryl Jones in a news release, adding that the company is already benefiting greatly from their participation.
Against the backdrop of the Ministry of Health working to enact the new cannabis export guidelines and a corridor to Europe, it’s definitely “go time” for Isracann as it looks to cement its name as a part of the most transformative time in the storied history of cannabis in Israel.
Click Here To Receive Isracann’s Investor Presentation
To learn more about Isracann Biosciences Click Here
Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.